Bernstein Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best cheap strong buy stocks to buy now. Bernstein analyst William Pickering maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 19, assigning the stock a price target of $95.00.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q2 2025 results on August 4, with total revenues reaching $825 million, up 16% year-over-year and up 17% at constant currency year-over-year.

Management reported that non-GAAP diluted EPS for the quarter reached $1.44, up 50% year-over-year, while GAAP diluted earnings per share (EPS) was $1.23, up 124% year-over-year.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.